Literature DB >> 23062672

Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters.

Shorena Janelidze1, Filip Ventorp, Sophie Erhardt, Oskar Hansson, Lennart Minthon, John Flax, Martin Samuelsson, Lil Traskman-Bendz, Lena Brundin.   

Abstract

Chemokines constitute a class of small inflammatory proteins that control the chemotaxis of leukocytes. They are also present in the central nervous system (CNS) and contribute to diverse physiological functions, such as the regulation of cell migration, axonal growth and neuronal survival. It is to date not known whether chemokines in the CNS are affected in psychiatric disorders. In this study, chemokine levels were measured in the cerebrospinal fluid (CSF) of 137 psychiatric patients in conjunction to a suicide attempt, and 43 healthy controls. A subgroup of patients (n = 42) was followed up with blood samples 12 years after the initial CSF collection, when they did not show suicidal behavior. The follow-up chemokine levels were compared to those of psychiatric patients (n = 17) who had never attempted suicide. Ultra-sensitive chemokine multiplex immunoassay was used to quantify eotaxin-1 (CCL11), interferon gamma-induced protein-10 (IP-10, CXCL10), macrophage inflammatory protein-1β (MIP-1β, CCL4), monocyte chemotactic protein-1 (MCP-1, CCL2), MCP-4 (CCL13) and thymus and activation regulated chemokine (TARC, CCL17). Patients were diagnosed using DSM-III-R/DSM-IV, and assessed using the Comprehensive Psychopathological Rating Scale (CPRS), including subscales, and the Suicidal Intent Scale (SIS). CSF eotaxin-1, MIP-1β, MCP-1, MCP-4 and TARC were significantly lower in suicide attempters than in healthy controls. Low chemokine levels were specifically associated with psychotic symptoms and pain. In the samples collected at follow-up, TARC was significantly lower in suicide attempters compared to psychiatric patients who had never attempted suicide. We also found a positive correlation between blood TARC and brain-derived neurotrophic factor (BDNF) levels. Our study thus provides evidence of reduced chemokine levels in suicide attempters, both in the acute suicidal setting, and at long-term, compared to non-attempters. These results warrant future studies on the detailed neurobiological functions of chemokines in psychiatric patients.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23062672     DOI: 10.1016/j.psyneuen.2012.09.010

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  19 in total

Review 1.  Inflammatory markers and suicidal attempts in depressed patients: A review.

Authors:  Stefano Marini; Federica Vellante; Ilaria Matarazzo; Domenico De Berardis; Nicola Serroni; Daniela Gianfelice; Luigi Olivieri; Fulvia Di Renzo; Anna Di Marco; Michele Fornaro; Laura Orsolini; Alessandro Valchera; Felice Iasevoli; Monica Mazza; Giampaolo Perna; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Int J Immunopathol Pharmacol       Date:  2016-01-04       Impact factor: 3.219

Review 2.  Suicide Biomarkers to Predict Risk, Classify Diagnostic Subtypes, and Identify Novel Therapeutic Targets: 5 Years of Promising Research.

Authors:  Jenessa N Johnston; Darcy Campbell; Hector J Caruncho; Ioline D Henter; Elizabeth D Ballard; Carlos A Zarate
Journal:  Int J Neuropsychopharmacol       Date:  2022-03-17       Impact factor: 5.176

3.  Neuropsychiatric symptoms and seizure related with serum cytokine in epilepsy patients.

Authors:  Hye-Rim Shin; Kon Chu; Woo-Jin Lee; Han Sang Lee; Eun Young Kim; Hyoshin Son; Jangsup Moon; Narae Kim; Ki-Young Jung; Keun-Hwa Jung; Soon-Tae Lee; Kyung-Il Park; Sang Kun Lee
Journal:  Sci Rep       Date:  2022-05-03       Impact factor: 4.996

4.  Chemokines gene expression in the prefrontal cortex of depressed suicide victims and normal control subjects.

Authors:  Ghanshyam N Pandey; Hooriyah S Rizavi; Runa Bhaumik; Hui Zhang
Journal:  Brain Behav Immun       Date:  2021-02-09       Impact factor: 7.217

Review 5.  Targeting the CCL2-CCR2 axis in depressive disorders.

Authors:  Katarzyna Curzytek; Monika Leśkiewicz
Journal:  Pharmacol Rep       Date:  2021-05-24       Impact factor: 3.024

Review 6.  The potential role of monocyte chemoattractant protein-1 for major depressive disorder.

Authors:  Chi-Un Pae
Journal:  Psychiatry Investig       Date:  2014-07-21       Impact factor: 2.505

Review 7.  A Potential Contribution of Chemokine Network Dysfunction to the Depressive Disorders.

Authors:  Joanna Ślusarczyk; Ewa Trojan; Jakub Chwastek; Katarzyna Głombik; Agnieszka Basta-Kaim
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

8.  A possible case of natalizumab-dependent suicide attempt: A brief review about drugs and suicide.

Authors:  Laura Mumoli; Miriam Ciriaco; Antonio Gambardella; Giuseppe Nicodemo Bombardiere; Paola Valentino; Caterina Palleria; Angelo Labate; Emilio Russo
Journal:  J Pharmacol Pharmacother       Date:  2013-12

9.  Increased astrocyte expression of IL-6 or CCL2 in transgenic mice alters levels of hippocampal and cerebellar proteins.

Authors:  Donna L Gruol; Khanh Vo; Jennifer G Bray
Journal:  Front Cell Neurosci       Date:  2014-08-14       Impact factor: 5.505

10.  Exploring the Determinants of Suicidal Behavior: Conventional and Emergent Risk (DISCOVER): a feasibility study.

Authors:  Zainab Samaan; Monica Bawor; Brittany B Dennis; Wala El-Sheikh; Jane DeJesus; Sumathy Rangarajan; Judith Vair; Heather Sholer; Nicole Hutchinson; Elizabeth Iordan; Pam Mackie; Shofiqul Islam; Mahshid Deghan; Jennifer Brasch; Lehana Thabane
Journal:  Pilot Feasibility Stud       Date:  2015-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.